| scholarly article | Q13442814 |
| P50 | author | Zeev Estrov | Q64026337 |
| P2093 | author name string | Bharat B Aggarwal | |
| Moshe Talpaz | |||
| Alok C Bharti | |||
| Shishir Shishodia | |||
| James M Reuben | |||
| Donna Weber | |||
| Raymond Alexanian | |||
| Saroj Raj-Vadhan | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| multiple myeloma | Q467635 | ||
| apoptotic process | Q14599311 | ||
| P304 | page(s) | 3175-3184 | |
| P577 | publication date | 2003-12-18 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis | |
| P478 | volume | 103 |
| Q37284373 | A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma |
| Q36962588 | A novel small molecule agent displays potent anti-myeloma activity by inhibiting the JAK2-STAT3 signaling pathway |
| Q47557930 | A simply synthesized biphenyl substituted piperidin-4-one for the fluorescence chemosensing of Cd2. |
| Q35587194 | A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells |
| Q34077188 | A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma. |
| Q36331908 | Abnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK/STAT3 pathway and the progression of the disease in multiple myeloma. |
| Q37688978 | An inhibitor of cholesterol absorption displays anti-myeloma activity by targeting the JAK2-STAT3 signaling pathway |
| Q55049042 | Anti-myeloma Effects of Icariin Are Mediated Through the Attenuation of JAK/STAT3-Dependent Signaling Cascade. |
| Q35143496 | Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma |
| Q33843535 | Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts |
| Q33930178 | Apoptosis of multiple myeloma. |
| Q40406392 | Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells |
| Q38825870 | Berberine and Curcumin Target Survivin and STAT3 in Gastric Cancer Cells and Synergize Actions of Standard Chemotherapeutic 5-Fluorouracil |
| Q33879341 | Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells |
| Q89761694 | Bone Marrow Stromal Cell-Derived IL-8 Upregulates PVR Expression on Multiple Myeloma Cells via NF-kB Transcription Factor |
| Q36162703 | Bone marrow microenvironment and the identification of new targets for myeloma therapy |
| Q39724856 | Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells |
| Q41839288 | Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells. |
| Q39148665 | Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma. |
| Q36984165 | Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. |
| Q37109468 | Caffeic Acid Phenylethyl Ester and MG-132 Have Apoptotic and Antiproliferative Effects on Leukemic Cells But Not on Normal Mononuclear Cells |
| Q36587800 | Cancer and diet: How are they related? |
| Q36819371 | Cancer cell signaling pathways targeted by spice-derived nutraceuticals |
| Q55281764 | Celastrol Attenuates the Invasion and Migration and Augments the Anticancer Effects of Bortezomib in a Xenograft Mouse Model of Multiple Myeloma. |
| Q34695119 | Chemosensitization of tumors by resveratrol |
| Q55456143 | Constitutive Activation of STAT3 in Myeloma Cells Cultured in a Three-Dimensional, Reconstructed Bone Marrow Model. |
| Q39929790 | Coronarin D, a labdane diterpene, inhibits both constitutive and inducible nuclear factor-kappa B pathway activation, leading to potentiation of apoptosis, inhibition of invasion, and suppression of osteoclastogenesis |
| Q34094406 | Crotepoxide chemosensitizes tumor cells through inhibition of expression of proliferation, invasion, and angiogenic proteins linked to proinflammatory pathway |
| Q37378063 | Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? |
| Q38592538 | Curcumin and its analogues: a potential natural compound against HIV infection and AIDS. |
| Q64973191 | Curcumin as an Alternative Epigenetic Modulator: Mechanism of Action and Potential Effects. |
| Q37223850 | Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model |
| Q44602053 | Curcumin decreases cholangiocarcinogenesis in hamsters by suppressing inflammation-mediated molecular events related to multistep carcinogenesis |
| Q34580050 | Curcumin in cell death processes: a challenge for CAM of age-related pathologies |
| Q38927737 | Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups. |
| Q39802485 | Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappaB activity |
| Q40402530 | Curcumin suppresses growth and induces apoptosis in primary effusion lymphoma. |
| Q34480991 | Curcumin, an atoxic antioxidant and natural NFkappaB, cyclooxygenase-2, lipooxygenase, and inducible nitric oxide synthase inhibitor: a shield against acute and chronic diseases |
| Q28393316 | Curcumin-the paradigm of a multi-target natural compound with applications in cancer prevention and treatment |
| Q34071871 | Cyclodextrin-complexed curcumin exhibits anti-inflammatory and antiproliferative activities superior to those of curcumin through higher cellular uptake |
| Q37505517 | DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment |
| Q64246309 | Decoration of Anti-CD38 on Nanoparticles Carrying a STAT3 Inhibitor Can Improve the Therapeutic Efficacy Against Myeloma |
| Q33832937 | Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications |
| Q36835067 | Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors |
| Q33758929 | Diet components can suppress inflammation and reduce cancer risk |
| Q35023062 | Digitoflavone inhibits IκBα kinase and enhances apoptosis induced by TNFα through downregulation of expression of nuclear factor κB-regulated gene products in human pancreatic cancer cells |
| Q41785517 | Docosahexaenoic acid (DHA) promotes immunogenic apoptosis in human multiple myeloma cells, induces autophagy and inhibits STAT3 in both tumor and dendritic cells. |
| Q58552357 | Down-regulated G protein-coupled receptor kinase 6 leads to apoptosis in multiple myeloma MM1R cells |
| Q36467189 | Effect of connective tissue growth factor on protein kinase expression and activity in human corneal fibroblasts |
| Q38089497 | Efficacy of bortezomib as first-line treatment for patients with multiple myeloma |
| Q34279869 | Embelin suppresses osteoclastogenesis induced by receptor activator of NF-κB ligand and tumor cells in vitro through inhibition of the NF-κB cell signaling pathway |
| Q35132241 | Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies |
| Q34180255 | Epigenetic changes induced by curcumin and other natural compounds. |
| Q35178132 | Epigenetic regulation of inflammatory cytokines and associated genes in human malignancies |
| Q36948728 | Estrogenic or antiestrogenic therapies for multiple myeloma? |
| Q34959075 | Evaluation of effectiveness of herbal medication in cancer care: a review study |
| Q40415975 | Evidence for a phosphorylation-independent role for Ser 32 and 36 in proteasome inhibitor-resistant (PIR) IkappaBalpha degradation in B cells |
| Q34650781 | Frequent engagement of RelB activation is critical for cell survival in multiple myeloma |
| Q36379379 | From traditional Ayurvedic medicine to modern medicine: identification of therapeutic targets for suppression of inflammation and cancer. |
| Q92859346 | Functional interplay between NF-κB-inducing kinase and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma |
| Q24678660 | Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway |
| Q38480261 | Gene set enrichment analysis of the NF-κB/Snail/YY1/RKIP circuitry in multiple myeloma. |
| Q39597050 | Genetic Susceptibility to Bortezomib-Induced Peripheral Neuroropathy: Replication of the Reported Candidate Susceptibility Loci |
| Q24311010 | Genetic aspects of inflammation and cancer |
| Q36292888 | Growth factors and antiapoptotic signaling pathways in multiple myeloma |
| Q37997663 | High frequency of inherited variants in the MEFV gene in patients with hematologic neoplasms: a genetic susceptibility? |
| Q47253158 | Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma |
| Q50102610 | Ibrutinib targets microRNA-21 in multiple myeloma cells by inhibiting NF-κB and STAT3. |
| Q35833040 | Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3. |
| Q54557849 | Imatinib treatment inhibit IL-6, IL-8, NF-KB and AP-1 production and modulate intracellular calcium in CML patients. |
| Q35847977 | Indole-3-carbinol suppresses NF-kappaB and IkappaBalpha kinase activation, causing inhibition of expression of NF-kappaB-regulated antiapoptotic and metastatic gene products and enhancement of apoptosis in myeloid and leukemia cells |
| Q37316105 | Inflammation and cancer: how friendly is the relationship for cancer patients? |
| Q27023869 | JNK signalling in cancer: in need of new, smarter therapeutic targets |
| Q39896286 | Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo |
| Q33697369 | Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. |
| Q35962054 | Logic-Based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma Cells |
| Q36693111 | Metabolism pathways in chronic lymphocytic leukemia |
| Q33786861 | MicroRNA: important player in the pathobiology of multiple myeloma |
| Q35849287 | Microscale functional cytomics for studying hematologic cancers |
| Q49921429 | Multiple Myeloma and Bone: The Fatal Interaction |
| Q64890377 | Multiple Myeloma: What Do We Do About Immunodeficiency? |
| Q37340304 | Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders |
| Q37790694 | NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia |
| Q36189276 | Novel Lys63-linked ubiquitination of IKKβ induces STAT3 signaling |
| Q39477274 | Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders |
| Q83197527 | Nuclear BCL-10 expression is common in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia and does not correlate with p65 NF-kappaB activation |
| Q38343521 | Number of expressed cancer/testis antigens identifies focal adhesion pathway genes as possible targets for multiple myeloma therapy. |
| Q39642662 | Pasteurella multocidaToxin-Stimulated Osteoclast Differentiation Is B Cell Dependent |
| Q92814428 | Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers |
| Q53087536 | Phospho-flow detection of constitutive and cytokine-induced pSTAT3/5, pAKT and pERK expression highlights novel prognostic biomarkers for patients with multiple myeloma. |
| Q39029761 | Piceatannol exhibits selective toxicity to multiple myeloma cells and influences the Wnt/ beta-catenin pathway |
| Q36579136 | Platelet factor 4 induces cell apoptosis by inhibition of STAT3 via up-regulation of SOCS3 expression in multiple myeloma |
| Q35751362 | Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signaling |
| Q24655581 | Prevention of progression in monoclonal gammopathy of undetermined significance |
| Q37268965 | RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma |
| Q38945383 | Regulation of STAT3 and NF-κB activations by S-nitrosylation in multiple myeloma |
| Q34606004 | Restoration of chemosensitivity by bortezomib: implications for refractory myeloma. |
| Q49872904 | STAT3 expression is associated with poor survival in non-elderly adult patients with newly diagnosed multiple myeloma |
| Q37702595 | STAT3 overexpression promotes metastasis in intrahepatic cholangiocarcinoma and correlates negatively with surgical outcome |
| Q64987490 | STAT3: A Promising Therapeutic Target in Multiple Myeloma. |
| Q33762105 | Safe and targeted anticancer efficacy of a novel class of antioxidant-conjugated difluorodiarylidenyl piperidones: differential cytotoxicity in healthy and cancer cells |
| Q36966767 | Selectively targeting the toll-like receptor 9 (TLR9)--IRF 7 signaling pathway by polymer blend particles |
| Q24669938 | Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma |
| Q35120899 | Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?. |
| Q36246709 | Silencing STAT3 with short hairpin RNA enhances radiosensitivity of human laryngeal squamous cell carcinoma xenografts in vivo |
| Q39539030 | Single cell functional analysis of multiple myeloma cell populations correlates with diffusion profiles in static microfluidic coculture systems |
| Q26766724 | South Asian Medicinal Compounds as Modulators of Resistance to Chemotherapy and Radiotherapy |
| Q34354073 | Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma |
| Q34264226 | Sulforhodamine B restaining as a whole-cell label allows visualizing one more fluorochrome and its application in assaying protein nucleocytoplasmic distribution |
| Q38246639 | T cell-based targeted immunotherapies for patients with multiple myeloma |
| Q34134557 | TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells |
| Q37043776 | TNF-α, a good or bad factor in hematological diseases? |
| Q90002815 | TRAF3 regulates the oncogenic proteins Pim2 and c-Myc to restrain survival in normal and malignant B cells |
| Q28299055 | Targeting NF-kappaB in hematologic malignancies |
| Q40125230 | Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth |
| Q90292397 | Targeting STAT-3 signaling pathway in cancer for development of novel drugs: Advancements and challenges |
| Q33384287 | Targeting the UPS as therapy in multiple myeloma |
| Q35835298 | Targeting tumor proteasome with traditional Chinese medicine |
| Q34936837 | The curcumin analog EF24 targets NF-κB and miRNA-21, and has potent anticancer activity in vitro and in vivo |
| Q37718836 | The genetic architecture of multiple myeloma |
| Q34667865 | The multifaceted role of curcumin in cancer prevention and treatment. |
| Q58597547 | The short-term effect of histone deacetylase inhibitors, chidamide and valproic acid, on the NF‑κB pathway in multiple myeloma cells |
| Q36147288 | Thiocolchicoside suppresses osteoclastogenesis induced by RANKL and cancer cells through inhibition of inflammatory pathways: a new use for an old drug. |
| Q37008654 | Transcription factors as therapeutic targets in lymphoid malignancies |
| Q37915623 | Tripterygium wilfordii bioactive compounds as anticancer and anti-inflammatory agents. |
| Q37680154 | URI regulates tumorigenicity and chemotherapeutic resistance of multiple myeloma by modulating IL-6 transcription |
| Q27302812 | Withaferin A disrupts ubiquitin-based NEMO reorganization induced by canonical NF-κB signaling |
| Q51842272 | Zerumbone abolishes RANKL-induced NF-kappaB activation, inhibits osteoclastogenesis, and suppresses human breast cancer-induced bone loss in athymic nude mice. |
Search more.